GKOS GLAUKOS Corp stock chart & analysis
Conviction 9HealthcareScan · Fri, Nov 6, 2026GLAUKOS Corp (GKOS) closed at $224.41 (+2.01%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 63, RS Rating 98, -12.1% from its 52-week high, +98.6% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.
Why GKOS moved
From the StockSetups movers recaps that covered GKOS, newest first. A recap states what was known that day.
- After hours+18.6%
Glaukos rose 18.6% after the bell to $215.15 on about 1.88 million shares, versus a 20-day average of 1.03 million. Market cap is about $10.7B, the largest in this group.
After-Hours Movers Oct 28, 2026: Why NCPL, PRCH, LITX Jumped →
Financials as of Wed, Sep 30, 2026 · quarterly.
GKOS technical analysis
Trend
GKOS is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 25.8% above the 50-day ($178.25) and 55.5% above the 200-day ($144.22). ADX(14) at 36 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 63, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 98 puts its weighted 12-month performance ahead of about 98% of the US market.
Volume and volatility
Volume on the latest session ran 1.4× its 20-day average. It trades about $427.9M a day on average. ATR(14) is $13.14, 5.9% of price — its typical daily range. Chaikin Money Flow (-0.07) shows distribution.
Key levels
The chart pattern's support is $148.70 and its resistance $251.97. The 52-week range is $80.91 to $255.19; price is 12.1% below the high and 177.1% above the low. The VWAP anchored at the 52-week high is $232.44, above price.
Performance
GKOS returned -5.6% (1 week), +39.0% (1 month), +23.6% (3 months), +67.9% (6 months), +165.8% (1 year), +98.6% (year to date).
About GLAUKOS Corp
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Surgical & Medical Instruments & Apparatus · Listed 2015 · 1,094 employees
Recent news
- GLAUKOS Corp: 8-K filedSEC EDGAR · Fri, Nov 6, 2026
- SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Buys $75.3 Million More Glaukos on TuesdayYahoo Finance · Thu, Nov 5, 2026
- iShares S&P Mid-Cap 400 Growth (IJK) Buys $58 Million More Glaukos on TuesdayYahoo Finance · Thu, Nov 5, 2026
- iShares Core S&P Mid-Cap (IJH) Adds Glaukos and TechnipFMC on Nov. 3Yahoo Finance · Thu, Nov 5, 2026
- ETFs Bought $385.0 Million of Glaukos (GKOS) on TuesdayYahoo Finance · Thu, Nov 5, 2026
- Is Glaukos (GKOS) Still Cheap After Record Sales And Profit?Yahoo Finance · Wed, Nov 4, 2026
- Glaukos (GKOS) Joins The S&P 400, Is It Overvalued At Current Levels?Yahoo Finance · Tue, Nov 3, 2026
Insider activity
SEC Form 4 transactions in GKOS · open-market 3 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Kliman Gilbert H Director · Common Stock · 2026-11-04 | Sell | 2.5K | $633K | 2026-11-04 | 2026-11-05 |
Kliman Gilbert H Director · Common Stock · 2026-11-04 | Exercise | 2.5K | $64K | 2026-11-04 | 2026-11-05 |
Kliman Gilbert H Director · Stock Option (Right to Buy) · 2026-11-04 | Exercise | 2.5K | — | 2026-11-04 | 2026-11-05 |
WEISNER AIMEE S Director · Common Stock · 2026-10-30 | Gift | 2.38K | — | 2026-10-30 | 2026-11-03 |
Navratil Tomas CHIEF DEVELOPMENT OFFICER · Stock Option (Right to Buy) · 2026-10-30 | Exercise | 8.79K | — | 2026-10-30 | 2026-11-03 |
WEISNER AIMEE S Director · Common Stock · 2026-10-30 | Gift | 2.38K | — | 2026-10-30 | 2026-11-03 |
Navratil Tomas CHIEF DEVELOPMENT OFFICER · Common Stock · 2026-10-30 | Exercise | 4.18K | $230K | 2026-10-30 | 2026-11-03 |
Navratil Tomas CHIEF DEVELOPMENT OFFICER · Common Stock · 2026-10-30 | Exercise | 8.79K | $755K | 2026-10-30 | 2026-11-03 |
Navratil Tomas CHIEF DEVELOPMENT OFFICER · Common Stock · 2026-10-30 | Sell | 10.22K | $2.4M | 2026-10-30 | 2026-11-03 |
Navratil Tomas CHIEF DEVELOPMENT OFFICER · Common Stock · 2026-10-30 | Sell | 12.84K | $3.1M | 2026-10-30 | 2026-11-03 |
SEC filings
EDGAR filings in GKOS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.